Sue Desmond-Hellmann joins the marquee crowd of biopharma experts at GV booting up a new generation of drug hunters
Sue Desmond-Hellmann has started the next chapter of her storied career in biopharma.
GV — the venture group formerly known as Google Ventures — has opened its doors to add her to their list of marquee drug experts.
David Schenkein, who made the leap to GV after starting from scratch to build Agios into a commercial-stage biotech in 10 years, offered his thumbs-up on Twitter after GV put out the word online that Desmond-Hellmann would be joining them as a senior adviser.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.